Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Bioscience company expands development program for EGFR inhibitor nimotuzumab
July 24th, 2005
YM BioSciences Inc. (YMBA), a cancer drug development company, announced that its subsidiary, CIMYM Inc., has partnered with Kuhnil Pharmaceutical Company of Seoul, Korea, to expand the development program for nimotuzumab (TheraCIM-hR3), its monoclonal antibody against the EGF receptor, for specific population of patients with non small cell lung cancer (NSCLC). Kuhnil will join the joint development team, comprising YM, Oncoscience A.G. and CIMAB S.A. management, to oversee the development of nimotuzumab. Kuhnil will fund Korean development costs and provide an undisclosed amount of up-front, milestone and royalty payments. In addition, Kuhnil will...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
